IL1RL2 and Alzheimer disease: Bissonnette et al. conducted a phase 2a proof-of-concept study involving 51 adult patients with moderate-to-severe AD to evaluate the effectiveness of spesolimab, an anti-IL36R antibody (Figure 2b).